Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer

20251 citationsJournal Article

Authors

CMS4 might be an additional biomarker of anti-EGFR treatment efficacy in RAS (and BRAF) WT mCRC.

Published in: Journal of Clinical Oncology

Volume 44, Issue 1, pp. 31-41

Field-Weighted Citation Impact: 1.05